99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer and Compared With 68Ga-PSMA-11 PET
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY
99mTc-QULIC-5-P1 is a new radiotracer targeting PSMA, which is promising as an excellent imaging agent applicable to PSMA positive prostate cancer. This study will investigate the safety, biodistribution and potential usefulness of 99mTc-QULIC-5-P1 SPECT imaging for the diagnosis of lesions in PSMA positive prostate cancer.
Eligibility
Participation Requirements
Sex: Male
Minimum Age: 18
Healthy Volunteers: t
View:
• At least 18 years of age.
• Signed informed consent.
• Patients with suspected or newly diagnosed or previously prostate cancer, with PSMA positive expression (supporting evidence may include MRI, CT, and pathology report, etc).
Locations
Other Locations
China
The First Affiliated Hospital of Chongqing Medical University
RECRUITING
Chongqing
Contact Information
Primary
Xiaoyang Zhang, PhD
zhangxy@mail.bnu.edu.cn
023-89011755
Time Frame
Start Date: 2024-05-20
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 30
Treatments
Experimental: 99mTc-QULIC-5-P1
Patients will receive a single administration of 99mTc-QULIC-5-P1
Related Therapeutic Areas
Sponsors
Leads: First Affiliated Hospital of Chongqing Medical University